Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “add” rating restated by equities research analysts at Numis Securities Ltd in a note issued to investors on Thursday. They currently have a GBX 1,560 ($20.25) price objective on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 17.38% from the stock’s previous close.
A number of other equities analysts have also issued reports on the company. Jefferies Group LLC decreased their price objective on Hikma Pharmaceuticals Plc from GBX 1,450 ($18.82) to GBX 1,390 ($18.04) and set an “underweight” rating for the company in a report on Wednesday, June 28th. J P Morgan Chase & Co decreased their price target on Hikma Pharmaceuticals Plc from GBX 2,400 ($31.16) to GBX 1,800 ($23.37) and set a “neutral” rating for the company in a research note on Friday, May 12th. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 1,800 ($23.37) price target on shares of Hikma Pharmaceuticals Plc in a research note on Friday, May 5th. Barclays PLC reaffirmed an “overweight” rating and set a GBX 2,200 ($28.56) price target on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Finally, Citigroup Inc. reaffirmed a “neutral” rating and set a GBX 1,550 ($20.12) price target on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals Plc has a consensus rating of “Hold” and an average target price of GBX 1,873.10 ($24.32).
Shares of Hikma Pharmaceuticals Plc (LON HIK) opened at 1199.00 on Thursday. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,198.00 and a 12-month high of GBX 2,354.00. The stock has a 50 day moving average price of GBX 1,395.71 and a 200 day moving average price of GBX 1,764.22. The firm’s market capitalization is GBX 2.89 billion.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.
